The four-tiered peritoneal regression grading score (PRGS) assesses the response to chemotherapy in peritoneal metastasis (PM). The PRGS is used, for example, to assess the response to pressurised intraperitoneal aerosol chemotherapy (PIPAC). However, the reproducibility of the PRGS is currently unknown. We aimed to evaluate the inter-and intraobserver variability of the PRGS. Methods and results: Thirty-three patients who underwent at least three PIPAC treatments as part of the PIPAC-OPC1 or PIPAC-OPC2 clinical trials at Odense University Hospital, Denmark, were included. Prior to each therapy cycle, peritoneal quadrant biopsies were obtained and three haematoxylin and eosin (H&E)-stained step sections were scanned and uploaded to a pseudonymised web library. For determining interobserver variability, eight pathologists assessed the PRGS for each quadrant biopsy, and Krippendorff's alpha and intraclass correlation coefficients (ICCs) were calculated. For determining intraobserver variability, three pathologists repeated their own assessments and Cohen's kappa and ICCs were calculated. A total of 331 peritoneal biopsies were analysed. Interobserver variability for PRGS of each biopsy and for the mean and maximum PRGS per biopsy set was moderate to good/ substantial. The intraobserver variability for PRGS of each biopsy and for the mean and maximum PRGS per biopsy set was good to excellent/almost perfect. Conclusions: Our data support the PRGS as a reproducible and useful tool to assess response to intraperitoneal chemotherapy in PM. Future studies should evaluate the prognostic and predictive role of the PRGS.
Introduction
Despite the development of new molecular techniques, histological assessment remains the gold standard in the diagnosis of most human malignancies. The effect of treatment (e.g. chemotherapy) on malignant tumour tissue -in the primary tumour as well as in its metastases -is assessed by histological characteristics such as fibrosis, acellular mucin pools, hyalinosis and/or infarct-like necrosis, resulting in a relative reduction of viable tumour cells. 1 Hence, these regressive features can be used to identify subpopulations of patients who are most likely to benefit from a given therapy. Most published scoring systems for the assessment of the histological response to neoadjuvant treatment are based on surgical resection specimens of the primary tumour or metastases. [2] [3] [4] [5] [6] [7] In 2016, the four-tiered peritoneal regression grading score (PRGS) for the histological assessment of response to therapy in peritoneal metastasis (PM) was proposed by a group of European pathologists. 8 The PRGS is potentially clinically important in the assessment of histological response to intraperitoneal chemotherapy, particularly when such a therapy is given several times and the decision as to whether the patient should receive additional treatment depends on the histological response. A novel example of such a treatment is the pressurised intraperitoneal aerosol chemotherapy (PIPAC), where chemotherapeutics are aerosolised within the peritoneal cavity during a standard laparoscopy at a capnoperitoneum. [9] [10] [11] Currently, PIPAC is an experimental treatment, and randomised, controlled trials are lacking at present. 12, 13 However, PIPAC seems to be a safe procedure, able to induce objective histological regression, to improve quality of life and to result in improved survival. [14] [15] [16] [17] [18] The inter-and intraobserver variability in assessing the PRGS in PM as well as its prognostic or predictive value are not known. However, the accuracy of current imaging systems for detection and therapy response assessment of PM is limited, and the PRGS is rapidly gaining clinical acceptance. [17] [18] [19] [20] [21] In this study, we evaluated the reproducibility of the PRGS in PM. Specific questions regarded the inter-and intraobserver variability, possible changes in accuracy during the course of therapy and the reproducibility of the maximal regression score versus the mean regression score. Our study included peritoneal biopsies with PM deriving from a wide range of different primary tumours, scored by a group of pathologists with varying experience.
Methods

S T U D Y D E S I G N
We performed an observational, retrospective, longitudinal, single-blinded study. The study was approved by the Data Protection Agency of the Region of Southern Denmark (17/30427). One pathologist from each participating centre signed a Data Processor Agreement, issued by the Data Protection Agency of the Region of Southern Denmark. All patients were part of the PIPAC-OPC1 (NCT02320448, n = 27) or PIPAC-OPC2 [EudraCT provided, GCP monitored (EudraCT 2016-003394-18), n = 6] clinical trials, approved by the Ethics Committee of the Region of Southern Denmark (S-20140211, S-20160100).
All peritoneal biopsies were obtained from 33 patients with PM treated at Odense PIPAC Centre (OPC), Odense University Hospital, Denmark, during the course of repeated PIPAC cycles. Based on current evidence, patients with PM of colorectal or appendiceal origin were treated with oxaliplatin 92 mg/m 2 in 150 ml dextrose, while patients with PM of other origin were treated with a combination of cisplatin 7.5 mg/m 2 in 150 ml saline and doxorubicin 1.5 mg/m 2 in 50 ml saline. 18 A total of 331 peritoneal biopsies were evaluated, with three step sections per biopsy, resulting in a total of 993 step sections. The included patients had PM derived from different primary tumours of different origin (Table 1) .
P E R I T O N E A L B I O P S Y S P E C I M E N S
All patients included in this study underwent at least three PIPAC procedures, and peritoneal quadrant biopsies were taken from all patients prior to each PIPAC procedure. According to current recommendations, biopsies were taken from areas macroscopically suspect for tumour in all four abdominal quadrants, if technically possible. In some instances, however, only one, two or three peritoneal biopsies could be taken for technical reasons. After obtaining the first set of biopsies prior to PIPAC treatment 1, the biopsy sites were marked with metal clips to ensure that subsequent biopsies were collected from the same sites. In order to ensure optimal fixation for reliable histopathological analysis, biopsies were fixed in 10% buffered formalin for 24-48 h. Then, samples were embedded in paraffin using a controlled temperature. Two series of three 4-to 5-lm-thick step sections from each biopsy were stained with haematoxylin and eosin (H&E) at the Department of Pathology, Odense University Hospital (OUH), Denmark.
W E B L I B R A R Y
All quantitative evaluation was performed on digitalised H&E-stained slides. From the two available H&E-stained step sections, the slide with the greater tissue area was scanned using a 920 objective on the NanoZoomer 2.0 HT whole slide scanner (Hamamatsu Photonics, Hamamatsu, Japan). The digitalised slides were uploaded to a pseudonymised web library. Each pathologist participating in this study received a personalised code to access the web library, and each access to the web library was logged.
P A T H O L O G I S T S
All slides were analysed online by eight independent pathologists from different institutes and different countries with diverse levels of practical experience in the assessment of histological regression grading in PM. Four of the participating pathologists were coauthors of the proposal article regarding the PRGS. 8 The other four pathologists were trained to become familiar with the PRGS system and were given a copy of the reference publication. 8 They were also taught to use the histological regression criteria. Five pathologists were senior consultants, three of whom had had a special research interest in peritoneal pathology for >10 years, and three pathologists were residents in pathology with 2, 3 and 5 years of working experience in pathology. All eight pathologists were involved in the assessment of interobserver variability and assigned a PRGS score to each slide under investigation. Three pathologists (two senior consultants and one resident) repeated their own assessment with 5, 10 and 12 weeks between the assessments to determine the intraobserver variability.
The PRGS defines four categories, based on the presence of residual tumour cells and the extent of regressive features. Major histological features of regression are fibrosis, inflammation, hyalinosis, acellular mucin pools, ischaemic necrosis, accumulation of macrophages/multinucleated giant cells and granuloma formation. 8 PRGS 1 corresponds to a complete regression with absence of tumour cells ( Figure 1A , B); PRGS 2 to a major histological response with regressive features predominant over residual tumour cells ( Figure 1C) ; PRGS 3 to a minor histological response with predominance of residual tumour cells over regressive features ( Figure 1D ); and PRGS 4 to a lack of histological response to therapy where the tumour cells are not accompanied by any regressive features ( Figure 1E -H). 8 According to the protocol, a PRGS was assessed for each quadrant biopsy. Moreover, the mean PRGS, based on the individual scores from the four quadrant biopsies, was given.
S T A T I S T I C S
In order to determine the inter-and intraobserver reproducibility, the statistical question is reliability of the measurements, defined as the extent to which measurements can be replicated. 22 For evaluating the interobserver agreement between multiple raters, Krippendorff's alpha using ordinal data was calculated. Krippendorff's alpha can be used with any sample size, number of observers and type of data in addition to handling missing data appropriately. For evaluating the intraobserver agreement, Cohen's kappa was used. Cohen's kappa and Krippendorff's alpha take coefficients ranging from 0 (or In addition to the calculations above, intraclass correlation coefficients (ICCs) were calculated for inter-and intraobserver variability. ICC is a reliability index that reflects both degree of correlation and agreement between measurements. It has been widely used in conservative care medicine to evaluate interobserver, test-retest and intraobserver reliability of numerical or continuous measurements. For the interobserver variability, the ICCs were reported with 95% confidence intervals based on a single-rater, absolute agreement using the two-way random-effects model. For the intraobserver variability, the ICCs were reported with 95% confidence intervals based on a single-rater, absolute agreement using the twoway mixed-effects model. ICCs less than 0.5 are indicative of poor reliability, between 0.5 and 0.75 moderate reliability, between 0.75 and 0.9 good reliability and greater than 0.90 excellent reliability.
The statistical analyses were performed using Stata version 15 
Results
A total of 331 slides from 33 patients were prepared for evaluation. There were 106, 112 and 113 slides from PIPAC 1, 2 and 3. All except six slides were rated by all eight pathologists. In total, 2642 ratings were performed. The combined gradings from all pathologists at the different time-points (i.e. PIPAC treatments) are shown in Table 2 , demonstrating increasing frequency of lower PRGS scores from PIPAC 1 to PIPAC 3 (P < 0.001).
The interobserver variability for the PRGS of each quadrant biopsy (Table 3) as well as for the mean (Table 4) and maximum (Table 5 ) PRGS per quadrant biopsy set are given. The ICC ranged from 0.63 and 0.76, indicating moderate to good reliability. The Krippendorff's alpha coefficients ranged from 0.60 to 0.74 regarding each quadrant biopsy score and the mean score per biopsy set (Tables 3 and 4) , indicating substantial agreement. Agreement regarding the maximum PRGS per biopsy set was slightly lower, with Krippendorff's alpha coefficients ranging from 0.57 to 0.63, meaning moderate to substantial agreement. The difference between the mean PRGS per quadrant biopsy set from each single pathologist and the average mean PRGS per quadrant biopsy set from all eight pathologists' scorings is shown in Figure 2A . Similarly, the difference between the PRGS for each quadrant biopsy from each single pathologist and the average PRGS for each quadrant biopsy, calculated from all eight pathologists' scorings, is shown in Figure 2B . These differences were normally distributed, and the large majority of scorings did not differ more than 0.5 PRGS from the mean values. Even though the PRGS decreased from PIPAC 1 to PIPAC 3, reliability did not deteriorate over time and was not modified by increased regression. The intraobserver variabilities are given for the PRGS of each quadrant biopsy (Table 6 ) as well as for the mean (Table 7) and maximum (Table 8) PRGS per quadrant biopsy set. The ICC varied between 0.87 and 1.00, reflecting good to excellent intraobserver reproducibility. Kappa coefficients varied from 0.89 to 0.98, indicating almost perfect agreement. Table 9 shows the interobserver variability between groups at PIPAC 1 and 2. We compared senior consultants (n = 5) with residents (n = 3) and 'authors of the proposal article' with 'others'. In Table 10 , agreement regarding the scoring of the first 33% of the biopsies at each PIPAC was compared with the agreement regarding the last 67% among all pathologists (n = 8).
Discussion
In this observational, retrospective, longitudinal, single-blinded study, we found that the reproducibility of the PRGS for assessing histological response of PIPAC of PM is substantial. A total of 331 quadrant biopsies obtained from 33 patients with PM taken at three different time-points (prior to PIPAC treatments 1, 2 and 3) were evaluated. The interobserver agreement was moderate to good/substantial, and slightly better regarding the assessment of the mean PRGS per biopsy set compared to the maximum PRGS per biopsy set. When comparing the agreement between groups, residents had a slightly better agreement than senior consultants, and 'others' had a slightly better agreement than the authors of the article proposing the PRGS. 8 The intraobserver agreement was good to excellent/almost perfect. We found no training effect when comparing agreement at the first one-third of the scored biopsies with the remaining two-thirds.
The results of this study are encouraging, particularly when bearing in mind that the participating pathologists had less information than in the clinical setting. First, they did not have access to immunohistochemistry. Secondly, they did not have access to microscopic slides from the primary tumours. Thirdly, the participating pathologists were blinded regarding prior to which PIPAC treatment the biopsies were taken. Although the mean PRGS decreased from PIPAC 1 to PIPAC 3, there was no change in accuracy during the course of therapy. Thus, our study supports that the PRGS is a reproducible and useful tool to assess response to intraperitoneal chemotherapy in PM.
Most regression grading systems published so far do not require complementary immunohistochemical analysis. However, immunohistochemistry is an important adjunct in the routine practice of clinical pathology. In the PRGS setting, immunohistochemistry might allow identification of isolated tumour cells in inflamed scar tissue or clusters of tumour cells in heavily inflamed tissue that cannot not be visualised by H&E staining. Thus, it is likely that the reproducibility of the PRGS would have been higher if the pathologists participating in the present study had had access to immunohistochemistry. This may explain why one pathologist scored PRGS 2 instead of PRGS 1 in Figure 1A , and probably also why one pathologist scored PRGS 1 instead of PRGS 2 in Figure 1C . However, immunohistochemistry also seems to be a useful tool for the differentiation of PRGS 3 from PRGS 4, as illustrated in Figure 1E -H. We do not know whether or not the higher agreement between 'others' compared to agreement between the co-authors of the PRGS proposal article, and regarding the biopsies taken at PIPAC 1, the slightly higher agreement between residents compared to agreement between senior consultants, means that these scores are more correct. 8 It may, however, be speculated that the pathologists primarily not related to the PRGS development used the proposed PRGS criteria more stringently and categorically, while the scoring of pathologists who were involved in the PRGS proposal may have depended a little more on their subjective opinion.
For a long time, it has been acknowledged that the degree of histological regression may provide clues to the effectiveness of chemotherapy for a given tumour. Several histological tumour regression systems (TRGs) have been developed for the quantification of response to chemotherapy of various primary and metastatic cancers. The Mandard system, developed for oesophageal cancer and published in 1994, was used later in a wide range of other primary malignancies. 5 Examples of TRG systems for rectal cancer are the Dworak (1997) and R€ odel (2005) systems, and for colorectal liver metastases, the Rubbia-Brandt system (2007). 4, 6, 7 In 2014, Trakarnsanga et al. compared the concordance indices of four different TRGs (Mandard (three-and five-category), Dworak/ R€ odel (three-and five-category), Memorial Sloan Kettering Cancer Center (three-category) and American Joint Committee on Cancer and College of American Pathologists (AJCC/CAP) (four-category)) in a cohort of 563 patients with locally advanced rectal cancer, and concluded that the four-category AJCC/CAP TRG was the most accurate and should be adopted as the standard. 4, 5, 7, [23] [24] [25] [26] Six different TRG systems have been proposed so far for gastric cancer, including the results of a recent Delphi survey. 2, [27] [28] [29] [30] [31] Recently, a six-tiered and a condensed three-tiered chemotherapy response score (CRS) for tubo-ovarian high-grade serous carcinoma after neoadjuvant chemotherapy and interval debulking surgery has been proposed, and showed high reproducibility with a Kappa coefficient of 0.76 when using the condensed three-tiered system. 3, 32 The tumour response of PM from colon cancer was explored in terms of tumour growth and histology in tumour-bearing rats treated with hyperthermic intraperitoneal chemotherapy. 33 The mean number of apoptotic cells and bodies in the entire cancer cell population was determined by counting their numbers in five high-power fields of non-necrotic areas. The index represented the number of visible apoptotic cancer cells Table 9 . Interobserver variability between groups for scoring the mean PRGS per quadrant biopsy set at PIPAC no. 1 and PIPAC no. 2. The following groups were compared: senior consultants (n = 5) versus residents (n = 3) and 'authors of the proposal article' (n = 4) versus 'others' (n = 4) in these fields. In the clinical setting, the histological response in patients with PM from colorectal cancer (n = 144) treated with preoperative systemic chemotherapy was examined by determination of the percentage of viable tumour cells with respect to the area of each nodule. 34 The assessment was independent of the presence of chemotherapy-related tissue injury, fibrosis or necrosis. In gastric cancer patients, a four-category classification system was used to examine the histological effects of neoadjuvant bidirectional intraperitoneal-systemic chemotherapy on primary tumours and PM nodules. 35 Regardless of the approach used to quantify tumour response after neoadjuvant therapy, there is an urgent need for an objective, practical, reproducible and clinically relevant regression grading system for PM with acceptable inter-and intraobserver variation. To our knowledge, the PRGS is the first biopsy-based scoring system focusing on the assessment of histological response in the palliative setting in PM. 8 The fact that we included PM from a wide range of different primary malignancies and that all biopsies were taken by the same team of surgeons and processed at the same pathological department should be considered a strength. To date, the clinical value of the PRGS has not been fully elucidated, but several clinical trials using the PRGS as primary or secondary outcome are currently ongoing. 21, 36 A few studies have also reported a reduction of the mean PRGS after PIPAC treatment in 67-80% of patients, 17, 18, 37 and initial data indicate a trend for the prognostic significance of the PRGS. 37 It is currently not known whether the mean PRGS or the maximum PRGS bears the highest clinical value.
In conclusion, our study shows that the PRGS has moderate to good/substantial interobserver variability and good to excellent/almost perfect intraobserver variability for the assessment of response to treatment of PM. Our study also shows that PRGS can be used by younger pathologists without loss of accuracy. Future studies should address the prognostic and predictive role of the PRGS in peritoneal metastasis.
